EGFR and carcinoma: Interestingly, it has been found that EGFR-overexpressing breast cancer cells can develop resistance against tyrosine kinase inhibitors due to an increased cellular ROS level, indicating that antioxidant-mediated elimination of excessive ROS can be a potential strategy to treat patients with EGFR-mutated carcinomas [22].